VINC
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q1 | -0.96 | $0 | -$4M |
| 2024 Q4 | 4.22 | $1M | -$6M |
| 2024 Q3 | -1.41 | $0 | -$6M |
| 2024 Q2 | -0.32 | $0 | -$6M |
| 2024 Q1 | -2.11 | $0 | -$8M |
| 2023 Q4 | -0.84 | $1M | -$8M |
| 2023 Q3 | -1.65 | $0 | -$7M |
| 2023 Q2 | -1.97 | $0 | -$13M |